| 4.91 -0.04 (-0.81%) | 09-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.93 | 1-year : | 6.08 |
| Resists | First : | 5.08 | Second : | 5.21 |
| Pivot price | 4.95  |
|||
| Supports | First : | 4.88 | Second : | 4.06 |
| MAs | MA(5) : | 4.9 | MA(20) : | 5 |
| MA(100) : | 4.25  |
MA(250) : | 3.62 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 9.1 |
| RSI | RSI(14): 51.6 | |||
| 52-week | High : | 5.4 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DBTX ] has closed above bottom band by 34.2%. Bollinger Bands are 74.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.92 - 4.95 | 4.95 - 4.97 |
| Low: | 4.84 - 4.88 | 4.88 - 4.9 |
| Close: | 4.86 - 4.91 | 4.91 - 4.95 |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Wed, 03 Apr 2024
Decibel Therapeutics Shares Encouraging Preclinical Data From Hearing Loss Gene Therapy Programs - AOL
Wed, 09 Aug 2023
Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron - TipRanks.com - TipRanks
Wed, 09 Aug 2023
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal - InvestorPlace
Wed, 09 Aug 2023
Decibel Therapeutics stock rallies as Regeneron moves to buy the biotech company - MarketWatch
Wed, 09 Aug 2023
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs - GlobeNewswire
Wed, 09 Aug 2023
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 61.9 (%) |
| Shares Short | 111 (K) |
| Shares Short P.Month | 218 (K) |
| EPS | -2.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.7 % |
| Return on Equity (ttm) | -76.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|